Actively Recruiting

Phase Not Applicable
Age: 18Years - 60Years
All Genders
NCT07192081

Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy

Led by Dr. Waseem Ullah · Updated on 2025-09-25

116

Participants Needed

1

Research Sites

38 weeks

Total Duration

On this page

Sponsors

D

Dr. Waseem Ullah

Lead Sponsor

H

Hayatabad Medical Complex

Collaborating Sponsor

AI-Summary

What this Trial Is About

Laryngoscopy and intubation during laparoscopic cholecystectomy often cause sudden increases in heart rate and blood pressure, which can be harmful in some patients. Medications such as labetalol and lignocaine are commonly used to reduce this hemodynamic response. This randomized controlled trial at Hayatabad Medical Complex, Peshawar, will compare intravenous labetalol (0.25 mg/kg) and lignocaine (1.5 mg/kg), administered 3 minutes before laryngoscopy. A total of 116 patients undergoing elective laparoscopic cholecystectomy will be randomly assigned to either drug group. The primary goal is to determine which drug is more effective in keeping heart rate and mean arterial pressure within ±20% of baseline during and after intubation. The study will also record blood pressure trends, intubation details, rescue medications, and adverse events such as bradycardia or hypotension. Results will help guide anesthesiologists in selecting the safer and more effective option to maintain cardiovascular stability during surgery.

CONDITIONS

Official Title

Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy

Who Can Participate

Age: 18Years - 60Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • ASA Grade I and II
  • Age 18 to 60 years
  • Scheduled for elective laparoscopic cholecystectomy
  • Both genders
  • Provided informed consent
Not Eligible

You will not qualify if you...

  • Allergy to labetalol or lignocaine
  • Taking blood pressure medications for hypertension
  • ASA Grade III or higher
  • Having cardiovascular, kidney, liver, or endocrine diseases
  • Pregnant or breastfeeding
  • Body mass index 35 or higher
  • Expected difficult airway

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hayatabad Med Complex

Peshawar, Khyber Pakhtunkhwa, Pakistan, 25000

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here